Immunic, Inc., a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, has announced the appointment of Inderpal Singh as General Counsel, effective today. In his new role, Mr. Singh will be responsible for legal and compliance matters and will become part of the management…
Amplicore Inc., an early-stage biopharmaceutical company currently developing locally delivered and minimally invasive therapeutic solutions for musculoskeletal diseases, has closed its Series Seed round of funding at $4 million. Investments were led by Photon Fund, with participation from Industrial Technology Investment Corporation, Berkeley Catalyst Fund, and SVE Capital. “We are very pleased to have accomplished…